# Research progress on antiviral drugs and vaccines for severe fever with thrombocytopenia syndrome

## TL;DR

This paper reviews recent developments in antiviral drugs and vaccines for a dangerous viral disease called severe fever with thrombocytopenia syndrome.

## Contribution

The paper provides an updated review of recent advances in antiviral drug and vaccine development for SFTSV.

## Key findings

- Current drugs like ribavirin and favipiravir show controversial efficacy against SFTSV.
- No standard treatment or approved vaccines exist for SFTSV infection.
- Recent research and new technologies are opening new possibilities for drug and vaccine development.

## Abstract

Severe fever with thrombocytopenia syndrome (SFTS), caused by the SFTS virus (SFTSV), has emerged as a significant global public health threat. Infected patients may present with gastrointestinal, neurological, and cardiovascular ribavirin and favipiravir are currently used in clinical practice, their efficacy remains controversial, and treatment primarily relies on symptomatic and supportive care. To date, there is no standard treatment regimen for SFTSV infection, nor are there any approved vaccines. However, recent advances in SFTSV research and the application of novel technologies have opened new pathways for the development of antiviral drugs and vaccines. This review summarizes the latest progress in the development of therapeutic agents and vaccines against SFTSV, aiming to provide valuable insights for drug development and countermeasure strategies for SFTS.